Pistachio helps life sciences BD and commercial teams identify who to target, when to reach out, and why now — using what's actually changing inside companies.

David Lam
VP Data Science · AstraZeneca
His team is actively scaling ML infrastructure for molecular representations — exactly the problem your platform solves.
"Saw your post on scaling molecular representations — we've been working with teams hitting similar limits. Compare notes at Bio-IT?"
Sarah Chen
Head of Computational Bio · Roche
Teams scaling up AI/ML often need external platforms to accelerate — your timing is perfect as she builds.
"Noticed your team is scaling up AI/ML — happy to share what's worked for similar buildouts. Free for coffee at Bio-IT?"
Michael Torres
Dir. External Innovation · Novartis
He's the decision-maker for AI partnerships and has a track record of closing deals with companies like yours.
"Looking forward to your panel — we've helped accelerate a few AI partnerships in this space. Would love to connect after."
9.5 hours of research saved on this page alone —signals updated in real-time
The problem: As an early team, everyone could be a customer — which means no one is a priority.
Pistachio: Helps startups narrow a broad pharma and biotech landscape into a focused list of accounts most likely to be receptive right now, based on real activity.
The problem: Cold outreach sounds generic because timing is unclear.
Pistachio: For each prioritized account, provides clear context on what has changed recently — giving founders a concrete reason to reach out now.
The problem: Reaching the wrong team wastes your best early shots.
Pistachio: Connects account activity to the teams and roles most likely to feel the pain, helping focus on stakeholders who can evaluate and champion a new product.
The problem: Early outreach feels risky when every message is a guess.
Pistachio: With account focus, timing context, and stakeholder clarity, teams can reach out with messages that feel informed and relevant — increasing reply rates.